Latest Period
Q2 2026
Security Snapshot
ORAMED PHARMACEUTICALS INC. - Common Stock (ORMP) Institutional Ownership
CUSIP: 68403P203
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
84
Shares (Excl. Options)
16,773,404
Price
$4.81
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ORMP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 16,773,404
- Total 13F value
- $80,666,594
- Portfolio coverage rank
- 0%
- Share change
- +3,521,330
- Value change
- +$17,107,819
- Number of holders
- 84
- Shares outstanding
- 41,592,301
- SEC-reported price per share
- $3.97
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock is tracked under CUSIP 68403P203.
- 84 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 63 to 84 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $45,015,766 to $80,666,594.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 84 institutions filings for Q2 2026.
Security key
68403P203
Latest holder period
Q2 2026
13F holders
84
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
ORMP full holder history
ORAMED PHARMACEUTICALS INC. SEC filings
ORAMED PHARMACEUTICALS INC. company facts
ORAMED PHARMACEUTICALS INC. insider transactions
ORAMED PHARMACEUTICALS INC. 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68403P203:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
ORMP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| KIDRON NADAV | 7.6% | $6,638,633 | 3,116,729 | Nadav Kidron | 11 Feb 2025 | |||
| Aquamarine Financial (Cayman) Ltd | 6% | +20% | $11,480,640 | +$2,122,870 | 2,512,175 | +23% | Aquamarine Financial (Cayman) Ltd | 30 Jun 2026 |
| BML Investment Partners, L.P. | 2.5% | -72% | $4,094,813 | -$9,022,435 | 1,026,269 | -69% | Leonard Braden Michael | 26 Jun 2026 |
As of 30 Jun 2026, 84 institutional investors reported holding 16,773,404 shares of ORAMED PHARMACEUTICALS INC. - Common Stock (ORMP). This represents 40% of the company’s total 41,592,301 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
38%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | 9.2% | 3,810,540 | +99% | 0.02% | $18,328,697 |
| Aquamarine Financial (Cayman) Ltd | 6% | 2,512,175 | +19% | 0.67% | $12,083,562 |
| Gem Investment Advisors, LLC | 4.8% | 1,998,802 | +22% | 5.9% | $9,614,238 |
| BlackRock, Inc. | 3.9% | 1,608,111 | +1644% | 0% | $7,735,015 |
| Murchinson Ltd. | 3.1% | 1,290,294 | -1.9% | 3% | $6,206,314 |
| BML Capital Management, LLC | 2.1% | 866,269 | -73% | 2.4% | $4,166,754 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.4% | 578,638 | -3.7% | 0.05% | $2,783,249 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 500,690 | +1962% | 0% | $2,408,318 |
| GOLDMAN SACHS GROUP INC | 0.61% | 253,293 | 0% | $1,218,339 | |
| STATE STREET CORP | 0.58% | 242,100 | 0% | $1,164,501 | |
| Rathbones Group PLC | 0.56% | 233,018 | 0% | 0% | $1,120,816 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.55% | 229,882 | 0% | $1,105,732 | |
| DIMENSIONAL FUND ADVISORS LP | 0.49% | 202,609 | +28% | 0% | $973,782 |
| NORTHERN TRUST CORP | 0.44% | 184,920 | 0% | $889,465 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.44% | 183,800 | +24% | 0% | $884,078 |
| WELLS FARGO & COMPANY/MN | 0.4% | 166,000 | +5.3% | 0% | $798,458 |
| BANK OF AMERICA CORP /DE/ | 0.36% | 150,694 | +3.1% | 0% | $724,838 |
| STRS OHIO | 0.32% | 133,800 | 0% | $643,578 | |
| JANE STREET GROUP, LLC | 0.27% | 113,349 | +116% | 0% | $545,209 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 0.25% | 102,962 | -12% | 0% | $495,247 |
| MARSHALL WACE, LLP | 0.25% | 101,953 | -61% | 0% | $490,393 |
| HRT FINANCIAL LP | 0.23% | 97,582 | +255% | 0% | $469,000 |
| Hillsdale Investment Management Inc. | 0.21% | 89,300 | -8.2% | 0.01% | $429,533 |
| RITHOLTZ WEALTH MANAGEMENT | 0.2% | 84,347 | -46% | 0.01% | $405,709 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.2% | 83,634 | 0% | $402,280 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 16,773,404 | $80,666,594 | +$17,107,819 | $4.81 | 84 |
| 2026 Q1 | 13,240,569 | $45,015,766 | +$7,189,264 | $3.40 | 63 |
| 2025 Q4 | 13,057,221 | $37,216,078 | -$220,532 | $2.85 | 57 |
| 2025 Q3 | 9,209,933 | $24,309,179 | +$25,894 | $2.64 | 47 |
| 2025 Q2 | 7,251,222 | $16,313,647 | -$1,132,788 | $2.25 | 47 |
| 2025 Q1 | 7,771,787 | $16,633,500 | +$194,000 | $2.14 | 52 |
| 2024 Q4 | 7,666,141 | $18,551,607 | +$1,150,587 | $2.42 | 56 |
| 2024 Q3 | 6,959,875 | $16,982,253 | +$2,490,137 | $2.44 | 55 |
| 2024 Q2 | 5,933,749 | $15,249,519 | +$1,726,907 | $2.57 | 58 |
| 2024 Q1 | 5,261,652 | $15,365,000 | +$367,171 | $2.92 | 51 |
| 2023 Q4 | 5,157,802 | $11,912,739 | +$6,481,828 | $2.31 | 56 |
| 2023 Q3 | 2,294,903 | $5,988,449 | -$130,636 | $2.61 | 55 |
| 2023 Q2 | 2,276,672 | $8,150,136 | -$6,048,074 | $3.58 | 50 |
| 2023 Q1 | 4,261,808 | $9,288,923 | -$8,600,260 | $2.18 | 58 |
| 2022 Q4 | 3,602,106 | $43,330,122 | +$3,052,928 | $12.03 | 75 |
| 2022 Q3 | 3,938,125 | $25,517,588 | -$15,544,475 | $6.48 | 66 |
| 2022 Q2 | 6,646,450 | $30,636,409 | -$17,757,938 | $4.58 | 81 |
| 2022 Q1 | 9,033,365 | $78,273,671 | -$349,248 | $8.65 | 99 |
| 2021 Q4 | 8,576,111 | $122,411,193 | +$40,878,901 | $14.28 | 114 |
| 2021 Q3 | 5,412,384 | $118,854,258 | +$35,544,918 | $21.98 | 91 |
| 2021 Q2 | 3,842,761 | $51,413,524 | +$35,140,443 | $13.38 | 73 |
| 2021 Q1 | 1,235,726 | $64,175,840 | +$52,410,474 | $10.16 | 43 |
| 2020 Q4 | 1,455,367 | $6,169,000 | -$1,608,413 | $4.24 | 36 |
| 2020 Q3 | 2,003,232 | $5,190,000 | +$1,670,327 | $2.61 | 34 |
| 2020 Q2 | 1,349,404 | $4,725,000 | +$2,515,869 | $3.53 | 31 |